Lane T, Smith D, Wancewicz E, Funk R
UCSD School of Medicine and Alliance Pharmaceutical Co., La Jolla, California.
Biomater Artif Cells Immobilization Biotechnol. 1993;21(2):163-72. doi: 10.3109/10731199309117354.
Endothelial cell (EC) activation plays a key role in the inflammatory response by promoting the margination of leukocytes in inflamed loci. Augmented leukocyte margination to activated EC is mediated by the increased display of leukocyte adhesion molecules on EC surface membranes. The biocompatibility of synthetic oxygen-transport fluids is intimately linked to EC function, since one of the first tissues encountered by such fluids is the vascular endothelium. We investigated the effect of one such agent, a phospholipid-based perfluorocarbon emulsion containing 90% w/v perfluorooctyl bromide (perflubron, PFOB) on EC activation. Human umbilical vein EC (HUVEC) were activated by 5 U/ml interleukin-1 (IL-1), 20 U/ml tumor necrosis factor (TNF), or 50 ng/ml E coli endotoxin (LPS) in the presence or absence of up to 20%, w/v perflubron. HUVEC activation was monitored by the extent of up-regulation of expression of intercellular adhesion molecule-1 (ICAM) and endothelial-leukocyte adhesion molecule-1 (ELAM). Exposure of HUVEC to perflubron did not alter the upregulation of ICAM or ELAM in response to IL-1 or TNF (n = 20). However, at 10% perflubron ICAM upregulation in response to LPS was inhibited by 95 +/- 6% (n = 9; p < .05). ELAM expression was similarly affected. The concentration of perflubron required to diminish LPS-induced up-regulation by 50% was 6.0 +/- 0.6% (n = 3). The inhibitory effect of 10% perflubron was overcome by > 1 microgram/ml LPS (n = 3) and the inhibitory effect was attenuated by adding perflubron to the cultures after LPS. In agreement with the above, additional experiments showed that incubation of LPS with perflubron prevented LPS-induced stimulation of TNF synthesis by a murine macrophage (RAW) cell line (n = 3). We conclude: 1) perflubron neither activates HUVEC nor interferes with HUVEC activation by IL-1 or TNF, 2) perflubron prevented HUVEC activation by LPS in a dose and time-dependent manner, 3) perflubron prevented LPS-induced activation of more than one cell line. Taken together, the data suggest that perflubron may bind and sequester limited concentrations of LPS. Whether this property of perflubron also occurs upon in vivo infusion and whether it might be clinically useful in preventing some of the adverse effects of endotoxemia are unknown.
内皮细胞(EC)激活通过促进白细胞在炎症部位的边缘化,在炎症反应中起关键作用。白细胞向激活的内皮细胞的增强边缘化是由内皮细胞表面膜上白细胞粘附分子的增加表达介导的。合成氧输送液的生物相容性与内皮细胞功能密切相关,因为这些液体首先遇到的组织之一是血管内皮。我们研究了一种这样的制剂,一种含有90%重量/体积全氟辛基溴(全氟溴辛烷,PFOB)的基于磷脂的全氟碳乳液对内皮细胞激活的影响。在存在或不存在高达20%重量/体积全氟溴辛烷的情况下,用人白细胞介素-1(IL-1)5 U/ml、肿瘤坏死因子(TNF)20 U/ml或大肠杆菌内毒素(LPS)50 ng/ml激活人脐静脉内皮细胞(HUVEC)。通过细胞间粘附分子-1(ICAM)和内皮细胞-白细胞粘附分子-1(ELAM)表达上调的程度监测HUVEC激活。将HUVEC暴露于全氟溴辛烷不会改变其对IL-1或TNF反应时ICAM或ELAM的上调(n = 20)。然而,在10%全氟溴辛烷时,对LPS反应的ICAM上调被抑制了95±6%(n = 9;p <.05)。ELAM表达也受到类似影响。将LPS诱导的上调减少50%所需的全氟溴辛烷浓度为6.0±0.6%(n = 3)。10%全氟溴辛烷的抑制作用被>1微克/ml LPS克服(n = 3),并且在LPS后将全氟溴辛烷添加到培养物中可减弱抑制作用。与上述一致,额外的实验表明,将LPS与全氟溴辛烷一起孵育可阻止LPS诱导的鼠巨噬细胞(RAW)细胞系TNF合成的刺激(n = 3)。我们得出结论:1)全氟溴辛烷既不激活HUVEC,也不干扰IL-1或TNF对HUVEC的激活;2)全氟溴辛烷以剂量和时间依赖性方式阻止LPS对HUVEC的激活;3)全氟溴辛烷阻止LPS诱导的不止一种细胞系的激活。综上所述,数据表明全氟溴辛烷可能结合并隔离有限浓度的LPS。全氟溴辛烷的这种特性在体内输注时是否也会出现,以及它在临床上是否可能有助于预防内毒素血症的一些不良反应尚不清楚。